Silencing or stimulation? siRNA delivery and the immune system

Annual Review of Chemical and Biomolecular Engineering

Volumn 2, Issue , 2011, Pages 77-96

  Whitehead, Kathryn A ^a   Dahlman, James E ^a   Langer, Robert S ^a,b   Anderson, Daniel G ^a,b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

2 modification; bifunctional siRNA; immunostimulatory RNA; isRNA; TLR7

Indexed keywords

BIFUNCTIONAL; BIOLOGICAL DATA; GENE SILENCING; GENETIC MANIPULATIONS; IMMUNE ACTIVATION; IMMUNE SYSTEMS; IMMUNOSTIMULATORY RNA; INNATE IMMUNE RESPONSE; INNATE IMMUNE SYSTEMS; ISRNA; RNA INTERFERENCE; SHORT INTERFERING RNA (SIRNA); SIRNA DELIVERY; TARGET GENES; THERAPEUTIC EFFECTS; TLR7;

GENETIC ENGINEERING; IMMUNOLOGY; RNA;

GENE THERAPY;

SMALL INTERFERING RNA; TOLL LIKE RECEPTOR;

CHEMICAL STRUCTURE; CHEMISTRY; GENE SILENCING; GENE TRANSFER; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; INNATE IMMUNITY; METHODOLOGY; REVIEW; RNA INTERFERENCE;

GENE SILENCING; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNITY, INNATE; IMMUNIZATION; MOLECULAR STRUCTURE; RNA INTERFERENCE; RNA, SMALL INTERFERING; TOLL-LIKE RECEPTORS;

EID: 79959407808     PISSN: 19475438     EISSN: None     Source Type: Journal    
DOI: 10.1146/annurev-chembioeng-061010-114133     Document Type: Review

References (117)

1. Judge AD, Robbins M, Tavakoli I, Levi J, Hu L, et al. 2009. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J. Clin. Investig. 119:661-73
2. Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, Bramlage B, et al. 2008. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl. Acad. Sci. USA 105:11915-20
3. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, et al. 2005. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23:1002-7 (Pubitemid 41114035)
4. DiFiglia M, Sena-Esteves M, Chase K, Sapp E, Pfister E, et al. 2007. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc. Natl. Acad. Sci. USA 104:17204-9 (Pubitemid 350211015)
5. Geisbert TW, Lee ACH, Robbins M, Geisbert JB, Honko AN, et al. 2010. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: A proof-of-concept study. Lancet 375:1896-905
6. Geisbert TW,Hensley LE, Kagan E, Yu EZ, Geisbert JB, et al. 2006. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J. Infect. Dis. 193:1650-57 (Pubitemid 43839469)
7. DavisME, Zuckerman JE, Choi CHJ, Seligson D, Tolcher A, et al. 2010. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464:1067-70
8. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. 1998. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806-11 (Pubitemid 28099681)
9. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. 2001. Duplexes of 21- nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-98 (Pubitemid 32494397)
10. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. 2001. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409:363-66 (Pubitemid 32151243)
11. Ameres SL, Martinez J, Schroeder R. 2007. Molecular basis for target RNA recognition and cleavage by human RISC. Cell 130:101-12 (Pubitemid 47031315)
12. Kleinschmidt WJ, Ellis LF, Van Fbank RM, Murphy EB. 1968. Interferon stimulation by a double stranded RNA of a mycophage in statolon preparations. Nature 220:167-68
13. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, et al. 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441:101-5
14. Xia H, Mao Q, Paulson HL, Davidson BL. 2002. siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol. 20:1006-10
15. Leirdal M, Sioud M. 2002. Gene silencing in mammalian cells by preformed small RNA duplexes. Biochem. Biophys. Res. Commun. 295:744-48 (Pubitemid 34756912)
16. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz A-L, Iggo R. 2003. Induction of an interferon response by RNAi vectors in mammalian cells. Nat. Genet. 34:263-64 (Pubitemid 36792856)
17. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BRG. 2003. Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 5:834-39 (Pubitemid 37087172)
18. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. 2005. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23:457-62 (Pubitemid 41724921)
19. Hoffmann JA, Kafatos FC, Janeway C, Ezekowitz RAB. 1999. Phylogenetic perspectives in innate immunity. Science 284:1313-18 (Pubitemid 29289650)
20. Iwasaki A, Medzhitov R. 2010. Regulation of adaptive immunity by the innate immune system. Science 327:291-95
21. Feve B, Bastard J-P. 2009. The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat. Rev. Endocrinol. 5:305-11
22. Locksley RM, Killeen N, Lenardo MJ. 2001. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 104:487-501 (Pubitemid 32201945)
23. Stuart LM, Ezekowitz RA. 2008. Phagocytosis and comparative innate immunity: Learning on the fly. Nat. Rev. Immunol. 8:131-41 (Pubitemid 351161303)
24. Liu Y-J. 2005. IPC: Professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 23:275-306 (Pubitemid 40563171)
25. Garcia-Sastre A, Biron CA. 2006. Type 1 interferons and the virus-host relationship: A lesson in detente. Science 312:879-82 (Pubitemid 43727313)
26. Janeway C Jr, Medzhitov R. 2002. Innate immune recognition. Annu. Rev. Immunol. 20:197-216 (Pubitemid 34293424)
27. Akira S, Uematsu S, Takeuchi O. 2006. Pathogen recognition and innate immunity. Cell 124:783-801 (Pubitemid 43261452)
28. Takeuchi O, Akira S. 2010. Pattern recognition receptors and inflammation. Cell 140:805-20
29. Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. 1998. A family of human receptors structurally related to Drosophila Toll. Proc. Natl. Acad. Sci. USA 95:588-93
30. Akira S, Takeda K, Kaisho T. 2001. Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat. Immunol. 2:675-80
31. Kawai T, Akira S. 2010. The role of pattern-recognition receptors in innate immunity: Update on Tolllike receptors. Nat. Immunol. 11:373-84
32. Bell J, Askins J, Hall P, Davies D, Segal D. 2006. The dsRNA binding site of human Toll-like receptor Proc. Natl. Acad. Sci. USA 103:8792-97 (Pubitemid 43878098)
33. Choe J, Kelker MS, Wilson IA. 2005. Crystal structure of human Toll-like receptor 3 (TLR3) ectodomain. Science 309:581-85 (Pubitemid 41033635)
34. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. 2001. Recognition of double-stranded RNA and activation of NF-?B by Toll-like receptor 3. Nature 413:732-38 (Pubitemid 33009951)
35. Wang T, Town T, Alexopoulou L, Anderson JF, FikrigE, FlavellRA. 2004. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat. Med. 10:1366-73 (Pubitemid 40022719)
36. Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, et al. 2008. Sequence- and targetindependent angiogenesis suppression by siRNA via TLR3. Nature 452:591-97 (Pubitemid 351483358)
37. Cho WG, Albuquerque RJC, Kleinman ME, Tarallo V, Greco A, et al. 2009. Small interfering RNAinducedTLR3activation inhibits blood and lymphatic vessel growth. Proc.Natl. Acad. Sci.USA106:7137-42
38. Kawai T, Akira S. 2008. Toll-like receptor and RIG-1-like receptor signaling. Ann. N. Y. Acad. Sci. 1143:1-20
39. Matsumoto M, Funami K, Tanabe M, Oshiumi H, Shingai M, et al. 2003. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J. Immunol. 171:3154-62 (Pubitemid 37093540)
40. Applequist SE, Wallin RPA, Ljunggren HG. 2002. Variable expression of Toll-like receptor in murine innate and adaptive immune cell lines. Int. Immunol. 14:1065-74
41. Bekeredjian-Ding IB, Wagner M, Hornung V, Giese T, Schnurr M, et al. 2005. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J. Immunol. 174:4043-50 (Pubitemid 40395980)
42. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, et al. 2002. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3:196-200 (Pubitemid 34141451)
43. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, et al. 2004. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303:1526-29 (Pubitemid 38314424)
44. Diebold SS, Kaisho T, Hemmi H, Akira S, Sousa CRE. 2004. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303:1529-31 (Pubitemid 38314425)
45. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, et al. 2004. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl. Acad. Sci. USA 101:5598-603
46. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, et al. 2005. Sequencespecific potent induction of IFN-a by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11:263-70 (Pubitemid 40460553)
47. Sioud M. 2005. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J. Mol. Biol. 348:1079-90
48. Lee J,Chuang T-H, RedeckeV, She L, Pitha PM, et al. 2003. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7. Proc. Natl. Acad. Sci. USA 100:6646-51 (Pubitemid 36666635)
49. Robbins M, Judge A, MacLachlan I. 2009. siRNA and innate immunity. Oligonucleotides 19:89-102
50. Forsbach A, Nemorin J, Montino C, Mueller C, Samulowitz U, et al. 2008. Identification of RNA sequencemotifs stimulating sequence-specific TLR8-dependent immuneresponses. J. Immunol. 180:3729-38
51. Gorden KKB, Qiu XX, Binsfeld CCA, Vasilakos JP, Alkan SS. 2006. Cutting edge: Activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides. J. Immunol. 177:6584-87 (Pubitemid 44715019)
52. Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, et al. 2005. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol. 174:1259-68
53. Zarember KA, Godowski PJ. 2002. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J. Immunol. 168:554-61 (Pubitemid 34049553)
54. Clemens MJ, Elia A. 1997. The double-stranded RNA-dependent protein kinase PKR: Structure and function. J. Interferon Cytokine Res. 17:503-24 (Pubitemid 27475916)
55. Yoneyama M, KikuchiM, Natsukawa T, Shinobu N, Imaizumi T, et al. 2004. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5:730-37 (Pubitemid 39023305)
56. Meurs E, Chong K, Galabru J, Thomas NSB, Kerr IM, et al. 1990. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell 62:379-90
57. Zhang Z, Weinschenk T, Guo K, Schluesener HJ. 2006. siRNA binding proteins of microglial cells: PKR is an unanticipated ligand. J. Cell. Biochem. 97:1217-29
58. Williams BRG. 2001. Signal integration via PKR. Sci. STKE 2001:re2
59. Marques JT, Devosse T, Wang D, Zamanian-Daryoush M, Serbinowski P, et al. 2006. A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nat. Biotechnol. 24:559-65
60. Puthenveetil S, Whitby L, Ren J, Kelnar K, Krebs JF, Beal PA. 2006. Controlling activation of the RNA-dependent protein kinase by siRNAs using site-specific chemical modification. Nucl. Acids Res. 34:4900-11 (Pubitemid 44605633)
61. Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, et al. 2006. 5'-Triphosphate RNA is the ligand for RIG-I. Science 314:994-97
62. Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, et al. 2006. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science 314:997-1001 (Pubitemid 44749946)
63. Kim D-H, Longo M, Han Y, Lundberg P, Cantin E, Rossi JJ. 2004. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat. Biotechnol. 22:321-25 (Pubitemid 38295765)
64. Kato H, Sato S, Yoneyama M, Yamamoto M, Uematsu S, et al. 2005. Cell type-specific involvement of RIG-I in antiviral response. Immunity 23:19-28 (Pubitemid 41019654)
65. Akira S, Uematsu S, Takeuchi O. 2006. Pathogen recognition and innate immunity. Cell 124:783-801 (Pubitemid 43261452)
66. Diebold S, Massacrier C, Akira S, Paturel C, Morel Y, Reis e Sousa C. 2006. Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides. Eur. J. Immunol. 36:3256-67 (Pubitemid 44932727)
67. Sioud M. 2006. Single-stranded small interfering RNA are more immunostimulatory than their doublestranded counterparts: A central role for 2'-hydroxyl uridines in immune responses. Eur. J. Immunol. 36:1222-30
68. Elmén J, Thonberg H, Ljungberg K, FriedenM,WestergaardM, et al. 2005. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucl. Acids Res. 33:439-47 (Pubitemid 40276964)
69. Dahlgren C, Wahlestedt C, Thonberg H. 2006. No induction of anti-viral responses in human cell lines HeLa andMCF-7 when transfecting with siRNA or siLNA. Biochem. Biophys. Res. Commun. 341:1211-17 (Pubitemid 43221793)
70. Fluiter K, Mook OR, Baas F. 2009. The therapeutic potential of LNA-modified siRNAs: Reduction of off-target effects by chemical modification of the siRNA sequence. Methods Mol. Biol. 487:189-203
71. Judge AD, Bola G, Lee ACH, MacLachlan I. 2006. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. 13:494-505 (Pubitemid 43257617)
72. Robbins M, Judge A, Liang L, McClintock K, Yaworski E, MacLachlan I. 2007. 2'-O-methyl-modified RNAs act as TLR7 antagonists. Mol. Ther. 15:1663-69 (Pubitemid 47289010)
73. Langkjær N, Pasternak A, Wengel J. 2009. UNA (unlocked nucleic acid): A flexible RNA mimic that allows engineering of nucleic acid duplex stability. Bioorg. Med. Chem. 17:5420-25
74. Bramsen JB, PakulaMM,Hansen TB,Bus C, LangkjaerN, et al. 2010.Ascreen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects. Nucl. Acids Res. 38:5761-73
75. Kenski DM, Cooper AJ, Li JJ, Willingham AT,Haringsma HJ, et al. 2010. Analysis of acyclic nucleoside modifications in siRNAs finds sensitivity at position 1 that is restored by 5'-terminal phosphorylation both in vitro and in vivo. Nucl. Acids Res. 38:660-71
76. Chiu Y-L, Rana TM. 2003. siRNA function in RNAi: A chemical modification analysis. RNA 9:1034-48 (Pubitemid 37093614)
77. Cekaite L, Furset G, Hovig E, Sioud M. 2007. Gene expression analysis in blood cells in response to unmodified and 2'-modified siRNAs reveals TLR-dependent and independent effects. J. Mol. Biol. 365:90-108 (Pubitemid 44830036)
78. Deleavey GF, Watts JK, Alain T, Robert F, Kalota A, et al. 2010. Synergistic effects between analogs of DNA and RNA improve the potency of siRNA-mediated gene silencing. Nucl. Acids Res. 38:4547-57
79. Hamm S, Latz E, Hangel D, Müller T, Yu P, et al. 2010. Alternating 2'-O-ribose methylation is a universal approach for generating non-stimulatory siRNA by acting as TLR7 antagonist. Immunobiology 215:559-69
80. Furset G, Sioud M. 2007. Design of bifunctional siRNAs: Combining immunostimulation and genesilencing in one single siRNA molecule. Biochem. Biophys. Res. Commun. 352:642-49 (Pubitemid 44880303)
81. Jackson AL, Burchard J, Leake D, Reynolds A, Schelter J, et al. 2006. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 12:1197-205 (Pubitemid 43990545)
82. Leuschner PJF, Ameres SL, Kueng S,Martinez J. 2006. Cleavage of the siRNA passenger strand during RISC assembly in human cells. EMBO Rep. 7:314-20
83. Czauderna F, FechtnerM,Dames S, Aygun H, Klippel A, et al. 2003. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucl. Acids Res. 31:2705-16 (Pubitemid 37442115)
84. Karikó K, Buckstein M, Ni H, Weissman D. 2005. Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23:165-75 (Pubitemid 41169286)
85. Heidel JD, Hu S, Liu XF, Triche TJ, Davis ME. 2004. Lack of interferon response in animals to naked siRNAs. Nat. Biotechnol. 22:1579-82 (Pubitemid 40039462)
86. Kornek M, Lukacs-Kornek V, Limmer A, Raskopf E, Becker U, et al. 2008. 1,2-Dioleoyl-3- trimethylammonium-propane (DOTAP)-formulated, immune-stimulatory vascular endothelial growth factor A small interfering RNA (siRNA) increases antitumoral efficacy in murine orthotopic hepatocellular carcinoma with liver fibrosis. Mol. Med. 14:365-73
87. Cubillos-Ruiz JR, Engle X, Scarlett UK, Martinez D, Barber A, et al. 2009. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J. Clin. Investig. 119:2231-44
88. Akinc A, ThomasM, Klibanov AM, Langer R. 2005. Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J. Gene Med. 7:657-63 (Pubitemid 40744532)
89. Love KT, Mahon KP, Levins CG, Whitehead KA, Querbes W, et al. 2010. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl. Acad. Sci. USA 107:1864-69
90. Nguyen DN, Chen SCY, Lu J, Goldberg M, Kim P, et al. 2009. Drug delivery-mediated control of RNA immunostimulation. Mol. Ther. 17:1555-62
91. Nguyen DN, Kim P, Mart́inez-Sobrido L, Beitzel B, Garćia-Sastre A, et al. 2009. A novel highthroughput cell-based method for integrated quantification of type I interferons and in vitro screening of immunostimulatory RNA drug delivery. Biotechnol. Bioeng. 103:664-75
92. Deleted in proof
93. Der SD, Zhou A, Williams BRG, Silverman RH. 1998. Identification of genes differentially regulated by interferon a, β, or ?using oligonucleotide arrays. Proc. Natl. Acad. Sci. USA 95:15623-28 (Pubitemid 29018750)
94. Robbins M, Judge A, Ambegia E, Choi C, Yaworski E, et al. 2008. Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum. Gene Ther. 19:991-99
95. Ko S-Y, Ko H-J, Chang W-S, Park S-H, Kweon M-N, Kang C-Y. 2005. α-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J. Immunol. 175:3309-17 (Pubitemid 41170552)
96. Lindqvist M, Persson J, Thorn K, Harandi AM. 2009. The mucosal adjuvant effect of a- galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J. Immunol. 182:6435-43
97. Ferrara N, Henzel WJ. 1989. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161:851-58 (Pubitemid 19162712)
98. Folkman J, Klagsbrun M. 1987. Angiogenic factors. Science 235:442-47 (Pubitemid 17009577)
99. Plate KH, Breier G, Weich HA, Risau W. 1992. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845-48
100. von Marschall Z, Scholz A, Cramer T, Schafer G, Schirner M, et al. 2003. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J. Natl. Cancer Inst. 95:437-48 (Pubitemid 36432418)
101. Folkman J, Ingber D. 1992. Inhibition of angiogenesis. Semin. Cancer Biol. 3:89-96
102. Brannon-Peppas L,Ghosn B, RoyK,Cornetta K. 2007. Encapsulation of nucleic acids and opportunities for cancer treatment. Pharm. Res. 24:618-27 (Pubitemid 46411970)
103. KriegAM. 2006. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5:471-84 (Pubitemid 44136959)
104. PriesR,Wulff S, KesselringR,Börngen K, XieL,WollenbergB. 2008. Up-regulation ofNKcell function against head and neck cancer in response to ss-isRNA requires TLR7. Int. J. Oncol. 33:993-1000
105. Poeck H, Besch R, Maihoefer C, RennM, Tormo D, et al. 2008. 5'-Triphosphate-siRNA: Turning gene silencing and Rig-I activation against melanoma. Nat. Med. 14:1256-63
106. Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, et al. 2008. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452:591-97 (Pubitemid 351483358)
107. Gantier MP, Tong S, Behlke MA, Irving AT, Lappas M, et al. 2010. Rational design of immunostimulatory siRNAs. Mol. Ther. 18:785-95
108. Goodchild A, Nopper N, King A, Doan T, Tanudji M, et al. 2009. Sequence determinants of innate immune activation by short interfering RNAs. BMC Immunol. 10:40
109. KortylewskiM, Swiderski P, Herrmann A,Wang L, Kowolik C, et al. 2009. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat. Biotechnol. 27:925-32
110. Iversen PO, Sorensen DR, Sioud M. 2010. A combined immunostimulatory and immunoinhibitory short interference RNA reduces hypercoagulability in a rat model of acute promyelocytic leukaemia. Thromb. Haemost. 104:350-54
111. Vaux DL, Cory S, Adams JM. 1988. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440-42
112. McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, et al. 1989. bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57:79-88 (Pubitemid 19098870)
113. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, et al. 1988. Detection of circulating tumor necrosis factor after endotoxin administration. N. Engl. J. Med. 318:1481-86
114. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, et al. 2006. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355:1018-28 (Pubitemid 44343545)
115. Krieg AM. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546-49
116. Hartmann G, Weiner GJ, Krieg AM. 1999. CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells. Proc. Natl. Acad. Sci. USA 96:9305-10 (Pubitemid 29374750)
117. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, et al. 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408:740-45 (Pubitemid 32015992)